Reproducibility Workshop Planning Committee 

K.C. Kent Lloyd (co-chair)

K.C. Kent Lloyd, DVM, PhD is a professional veterinarian and research physiologist with a scientific interest in mutant mouse biology. Kent Lloyd graduated with his Bachelor of Science degree from the University of California, San Diego, with an emphasis in biology and biochemistry.  He was accepted into the School of Veterinary Medicine at the University of California, Davis (UCD) from where he graduated in 1983 with his Doctor of Veterinary Medicine (DVM) degree.  After a clinical internship at the New Bolton Center, University of Pennsylvania School of Veterinary Medicine, surgery residency at the UCD Veterinary Medical Teaching Hospital (VMTH), and brief appointment as a clinical faculty member in the VMTH, Dr. Lloyd matriculated in the School of Medicine at the University of California, Los Angeles (UCLA) where he received his Doctor of Philosophy (Ph.D.) in Physiology under the mentorship of Doctors John H. Walsh and Jared Diamond in 1992. After graduation, he immediately joined the UCLA faculty as an Assistant Professor in the Department of Physiology where he established his NIH-funded research laboratory investigating the mechanisms of enterogastric reflexes. During the next 3 years, Dr. Lloyd served concurrently as a Visiting Scientist at the European Molecular Biology Laboratory in Heidelberg, Germany, where he engaged in pioneering work on conditional mutagenesis in the mouse.  After earning a promotion to Associate Professor in 1996, Dr. Lloyd was recruited to the School of Veterinary Medicine at UCD as a tenured faculty member in the Department of Anatomy, Physiology, and Cell Biology and as a founding faculty member of the Center for Comparative Medicine.  Within 5 years he was promoted to full Professor and in 2002 was appointed the Associate Dean for Research and Graduate Education. Dr. Lloyd is currently a Professor in the Department of Surgery in the UCD School of Medicine and Director of the Mouse Biology Program.  Dr. Lloyd has an active NIH-funded research program that emphasizes the development and application of genetically-altered mice for research that seeks to understand the biological functions of genes as well as the genetic basis of disease pathogenesis. He is an active participant in the education and training of undergraduate, graduate, and professional students and scholars.  He also serves on many school and campus wide committees, professional organizations such as Chair of the Council on Research at the American Veterinary Medical Association, and federal agencies, including as a member of the Council on Councils at the National Institutes of Health.  Dr. Lloyd lives in Davis, California, with his wife and 2 children.

Steven Niemi (co-chair)

Steven Niemi, DVM is Past President of the American College of Laboratory Animal Medicine (ACLAM) and currently serves as an ACLAM Officer.. With over 35 years of experience in biomedical research and commercial biotechnology, he has held senior management positions in contract drug and device development, gene therapy and genomics start-ups, and laboratory animal care. Dr. Niemi is a Diplomate and past President of the American College of Laboratory Animal Medicine as well as Chair of the Board of Directors, Massachusetts Society for Medical Research. He also co-chaired the NRC/ILAR Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents, and chaired the National Institute of Environmental Health Sciences/National Toxicology Program’s Scientific Advisory Committee on Alternative Toxicological Methods. In addition, he has served on the boards of the Biotechnology Industry Organization’s Food and Agriculture Governing Body, ILAR, Illinois Biotechnology Industry Organization, Massachusetts Biotechnology Council, National Association for Biomedical Research, Public Responsibility in Research & Medicine, and the Scientists Center for Animal Welfare, plus numerous national task forces addressing medical product development and lab animal welfare. Dr. Niemi earned an AB in biology from Harvard College, a DVM from Washington State University, and then received a US Public Health Service National Research Service Award while a Postdoctoral Fellow in the Division of Comparative Medicine at the Massachusetts Institute of Technology. He later completed the Program for Management Development at the Harvard Business School.

Bonnie V. Beaver

Bonnie Beaver, DVM is a professor in the Department of Small Animal Clinical Sciences in the College of Veterinary Medicine at Texas A&M University. She obtained her veterinary degree from the University of Minnesota and her Master’s degree from Texas A&M University. Besides having taught the classes in the basic sciences and clinical aspects of veterinary medicine, Dr. Beaver has an extensive background in the animal behavior and animal welfare.  She has a number of published books, book chapters, and scientific articles on these subjects and is a frequent speaker at veterinary continuing education seminars.  In addition to being named as a Charter Diplomate and first president of both the American College of Veterinary Behaviorists and the American College of Animal Welfare, Dr. Beaver has served as chair of several task forces and president of many other professional organizations including the Texas Veterinary Medical Association and American Veterinary Medical Association.

Brian R. Berridge

Brian Berridge, DVM, PhD, DACVP is Director of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GlaxoSmithKline.  In that position he leads efforts to advance the scientific robustness of animal and non-animal modeling in support of pharmaceutical development.  He has held previous positions as a Director of Regulatory & Discovery Pathology at GSK and Principal Research Pathologist at Eli Lilly & Company.  Brian is an Oklahoma State University-trained veterinarian with residency and PhD training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists and holds an adjunct Associate Professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina.  He is a member of the Executive Board and Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee, the Integrated CV Strategies Working Group, and the Translational Imaging Working Group.  Brian also chairs an international effort to harmonize cardiovascular nomenclature in regulatory toxicologic pathology and a CV Specialty Interest Group within the Society of Toxicologic Pathologists.

Pamela Chamberlain

Pamela Chamberlain, DVM, DABT, PhD is a veterinarian by training, holds a Ph.D. in toxicology, and is a Diplomate of the American Board of Toxicology.  Her professional experience includes private clinical practice, reviewer and food safety toxicologist with the Food and Drug Administration’s (FDA) Center for Veterinary Medicine, Temporary Advisor to the Joint FAO/WHO Expert Committee on Food additives for veterinary drugs, and Lead Delegate for the US Delegation to the Codex Committee on Residues of Veterinary Drugs in foods.  Dr. Chamberlain also worked for a contract research organization as a study director and study director manager specializing in the design and conduct of GLP preclinical safety/toxicity studies, and as Associate Director for Veterinary Services.  Currently with FDA, Dr. Chamberlain applies her diverse, experience, knowledge, and skills to help advance the regulatory science mission of the Office of the Commissioner’s Office of Counterterrorism and Emerging Threats. She is also the Institutional Official and manager of the FDA’s White Oak campus animal program, the FDA’s Liaison to the USDA-FDA-NIH Memorandum of Understanding for Laboratory Animal Welfare, and the FDA’s Designated Agency Representative to the Federal Veterinarian Talent Management Advisory Council.

Carol Clarke

Carol Clarke, DVM received her Bachelor’s degree in the Natural Sciences from Johns Hopkins University and her DVM degree from the Tuskegee School of Veterinary Medicine. After receiving her DVM, she practiced small animal medicine in New York City for 13 years before entering the laboratory animal medicine training program at SmithKline Beecham Pharmaceuticals located in King of Prussia, Pennsylvania. Upon completion of the program, she entered the National Institutes of Health in 1998 as the primate facility veterinarian for the Veterinary Resources Program.  In 2001, she accepted a position with the Comparative Medicine Branch of the National Institute of Allergy and Infectious Diseases (NIAID) and became a Diplomate of the American College of Laboratory Animal Medicine in 2005. During her 10 years with NIAID, she served as Institutional Animal Care and Use Committees coordinator, Vice Chair of the Rodent Gnotobiotic Committee, and Chief of Shared and Central Facility Operations.  In addition, she prepared all USDA, Office of Laboratory Animal Welfare, and Association for Assessment and Accreditation of Laboratory Animal Care, International annual reports. Carol Clarke accepted a position with the U.S. Department of Agriculture in 2011, and currently serves as the Research Specialist Staff Officer at APHIS-Animal Care Headquarters located in Riverdale, Maryland.  In her present position she writes policy, addresses public concerns, and works collaboratively with other federal agencies to reduce the numbers of live animals used in research.

Margaret S. Landi

Margaret Landi, VMD, MS is the Chief of Animal Welfare, Ethics and Strategy for GlaxoSmithKline.  She received an MS in Comparative Medicine after completing her veterinary training at the University of Pennsylvania.  Her first roles were in clinical laboratory animal and veterinary medicine. Dr. Landi is a Diplomate in the American College of Laboratory Animal Medicine (ACLAM) and is a Past-President of the organization.  Besides serving on the ACLAM Board of Directors, she has served on the Council of the Institute of Laboratory Animal Research (ILAR), of the National Academy of Sciences. While on Council, she was Editor-in-Chief of the ILAR Journal. Dr. Landi has served on review committees of the National Institutes of Health (NIH) and has led special site visit teams for NIH Committees. She currently serves on the Board of Trustees for the Scientists Center for Animal Welfare and the Board of Directors for the National Association for Biomedical Research; Americans for Medical Progress; and Chimp Haven, the only federally funded sanctuary for chimpanzees in the United States. Dr. Landi has received Distinguish Alumni Awards from the University of Pennsylvania School of Veterinary Medicine and William Paterson University. She has been awarded both the Charles River Prize and the Pennsylvania Veterinary Medical Association’s Veterinarian of the Year Award. She is also a recipient of the Harry Rowsell Award from the Scientists Center for Animal Welfare. Margaret Landi served on the Institute of Medicine’s Committee on the Future of Chimpanzees in Biomedical and Behavioral Research. The Committee published its report Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity in December 2011. She has published and presented papers on a number of topics related to laboratory animal medicine, welfare and science. Her most recent area of work is in the application of global principles for laboratory animals in an international arena with differing laws, cultures, regulations and policies.

Malcolm Macleod

Malcolm Macleod, PhD is Professor in Neurology and Translational Neuroscience at the Centre for Clinical Brain Sciences, University of Edinburgh, and Head of Neurological Diseases and Stroke at NHS Forth Valley. After undergraduate medical training (including a First Class Honours degree in Pharmacology) he trained in Internal Medicine before embarking on a PhD in the Butcher lab investigating the neuroprotective actions of FK506. This was followed by post-doctoral work in the Seckl lab defining a neuroprotective role for increased expression of the mineralocorticoid receptor. While this work continued he completed his training in Neurology, including a pivotal sabbatical year with Donnan at the National Stroke Research Institute, Melbourne, Australia. During this time he began an involvement with stroke clinical trials, and it was in an effort to identify suitable drugs for such clinical trials that he began to develop techniques to allow the systematic review and meta-analysis of data from animal studies. This led to the founding of the Collaborative Approach to Meta-analysis and Review of Animal Data from Experimental Studies (CAMARADES) in 2006. Since then these approaches have found application in a diversity of models, and the CAMARADES group, under his leadership, have build up considerable expertise in this area. He was on the writing committee for the Landis guidelines and is an investigator on the MultiPART program developing structures for multicentre animal studies. He has served on the UK Home Office Animals in Science Committee since 2013 and as chair of the 3Rs sub-committee. His clinical trial work continues as co-Chief Investigator of EuroHYP-1. He was the Allan and Maria Myers International Visiting Fellow at the University of Melbourne in 2011.

Brian C. Martinson

Brian Martinson, PhD, MS is a Senior Research Investigator at HealthPartners Institute for Education and Research (the Institute), and a Research Scientist in the Minneapolis VA Center for Chronic Disease Outcomes Research. He has more than 15 years of experience conducting health behavior related research (both interventional and observational), including more than ten years of experience leading several NIH funded research projects on research integrity. Starting in 2001, he led the first ever large-scale, nation-wide, survey-based study of research integrity in two samples of NIH funded researchers – one sample of Postdoctoral Fellows and the second of recent first “R01” grant recipients (“Work-Strain, Career Course and Research Integrity.” R01-NR08090; NIH-NINR). Following this, beginning in 2005, he led a second, related study conducted in a sample of 5000 academic faculty in the biomedical and social sciences at 50 of the top research universities in the US (“Procedural Justice, Identity, and Research Integrity.” R01-NS052885; NIH-NINDS). In 2009-2010, he served as a consultant to a three University Consortium participating in the Council of Graduate Schools’ “Project on Scholarly Integrity.” In that capacity he assisted in the development, fielding of, and report generation and dissemination of results from a pre-validated version of the research integrity climate assessment tool. That work was conducted in a sample of roughly 30,000 university personnel ranging from undergraduate and graduate students to lab-technicians to postdoctoral fellows to faculty, across a broad spectrum of academic disciplines. Also in 2009-2010, he served on an invited expert panel on research integrity, convened by the Council of Canadian Academies at the request of Industry Canada. From 2008 through middle 2012, he served as Co-PI of an NIH funded study developing and assessing the validity and reliability of a research integrity climate assessment survey (Co-PI: Carol Thrush; “Propagating the Uniform Research Integrity Climate Assessment (U-RICA).” R21-RR025279; NIH-NCRR). That work resulted in a tool called the Survey of Organizational Research Climate (SORC). Starting in January 2012 and running through 2014 he is serving as a member of a U.S. National Research Council panel charged with undertaking a revision of the 1992 publication, Responsible Science: Ensuring the Integrity of the Research Process. He has also recently begun a two year project he is leading in the VA, with funding from VA HSR&D, conducting an RCT using the SORC tool as part of a project testing the efficacy of a reporting and feedback intervention to improve research integrity climates in VA research settings.

Susan Brust Silk

Susan Brust Silk, MS is the Director of the Division of Policy and Education in the NIH Office of Laboratory Animal Welfare (OLAW) where she oversees the interpretation of Public Health Service Policy on Humane Care and Use of Laboratory Animals regarding the use of animals in research, testing and training at PHS-Assured institutions. She develops and directs educational programs in the ethical and humane care and use of laboratory animals including the OLAW Online webinar programs and the OLAW web resources. Before joining OLAW, Ms. Silk worked at the NIH National Cancer Institute (NCI), Office of the Director as the Senior Scientific Speechwriter and Special Communication Project Developer.  She served the NCI Intramural Program as Senior Animal Policy Advisor and Director of the Office of Mice Advice. Ms. Silk has conducted research on murine plasmacytomagenesis at NIH NCI and the Karolinska Institute. She directed transgenic mouse core laboratories at both NIH and the Johns Hopkins University School of Medicine. Ms. Silk has an MS in Immunology/Genetics from the University of Maryland, a BFA in Design and Fine Art from the Maryland Institute, College of Art.

 

Reproducibility Workshop Speakers and Panelists

Kathryn Bayne

Kathryn Bayne, MS, PhD, DVM, DACLAM, DACAW, CAAB is Global Director for the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). In this role she directs the accreditation program worldwide and travels extensively to advance AAALAC’s accreditation program and laboratory animal welfare. Prior to this position she worked at the National Institutes of Health leading a research program on nonhuman primate psychological well-being and environmental enrichment programs for primates, dogs, cats and swine. She is internationally renowned for her work in laboratory animal behavior and welfare. Dr. Bayne is a past president of the American College of Laboratory Animal Medicine (ACLAM), the Association of Primate Veterinarians, as well as the District of Columbia Veterinary Medical Association. She served on the boards of the American Society of Laboratory Animal Practitioners (ASLAP), the National Association for Biomedical Research, Lab Animal editorial board and as Vice President of the Scientists Center for Animal Welfare. She is past Chair of the American Veterinary Medical Association’s Animal Welfare Committee and recently served as the laboratory animal medicine representative on the AVMA’s Animal Welfare Advisory Committee, charged with developing over-arching animal welfare principles for the entire veterinary profession. She is also past Chair of ASLAP’s Animal Welfare Committee. Dr. Bayne was a charter member and Vice Chair of the International Association of Colleges of Laboratory Animal Medicine. Dr. Bayne served as a member of the National Academies’ Institute for Laboratory Animal Research (ILAR) Council. She served on the National Academies’ committee to revise the Guide for the Care and Use of Laboratory Animals (1996) and the National Academies’ committees on Psychological Well-Being of Nonhuman Primates, Occupational Health and Safety in the Care of Nonhuman Primates and Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. She was the recipient of the 1993 Henry and Lois Foster Award for high score on the ACLAM certifying examination and the recipient of AALAS’s prestigious Garvey award, which recognizes outstanding accomplishments relating to the humane treatment of animals used in biomedical research. Dr. Bayne is also the 2009 recipient of the American Veterinary Medical Association’s Animal Welfare Award and Washington State University’s 2009 Excellence in Research and Teaching Award. Most recently, she is the 2012 recipient of the Charles River Prize, which recognizes distinguished contributions to laboratory animal science. She is board certified in laboratory animal medicine and in animal welfare, and is a certified applied animal behaviorist.

Robert Bazell

Robert Bazell is adjunct professor of Molecular, Cellular and Developmental Biology at Yale University. He is the former chief science and health correspondent for NBC News. Dr. Bazell graduated from the University of California, Berkeley in 1967 with a BA in biochemistry and Phi Beta Kappa honors. He then traveled to England, where he studied biology at the University of Sussex in 1969 as part of his graduate work, before returning to Berkeley to complete his doctoral degree in immunology. Bazell continued pursuing his dual interest in journalism and science by joining Science magazine in 1971 and writing for its News and Comment section. A year later, he left the publication to become a reporter for the New York Post. In 1976, he began his long career in broadcast journalism by joining WNBC in New York as a reporter, before moving to NBC News. At NBC, Dr. Bazell was one of the first network news correspondents to report on the emerging AIDS crisis in the early 1980s. He was also a reporter and chief space correspondent during the Space Shuttle Challenger disaster, when he reported about the explosion of the Space Shuttle on the January 8th, 1986 episode of NBC Nightly News. In 1998, Bazell wrote and published HER-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer, which chronicled the creation of Herceptin, a drug used to treat breast cancer. He left NBC after 38 years in March 2013 to join Yale University’s adjunct faculty. Dr. Bazell’s extensive coverage in the 1980s of the nascent AIDS epidemic, including reports from the United States, Africa, Europe, the Caribbean and South America, earned him the Alfred I. duPont-Columbia Award and the Maggie Award from Planned Parenthood. He also earned two Emmys for his reports on the human brain, and has earned five Emmys in total. In 1993, Dr. Bazell was honored with the George Foster Peabody Award and the Hope Funds Award in Advocacy in 2008.

C. Glenn Begley

C. Glenn Begley, PhD is the Chief Scientific Officer and Senior Vice President at TetraLogic Pharmaceuticals, based in Malvern, PA. TetraLogic is a biotechnology company developing novel therapies for oncology and infectious diseases. Until January 2012, Dr. Begley was Vice President and Global Head of Hematology and Oncology Research for Amgen, Inc. He joined Amgen in 2002, and was responsible for building the hematology and oncology research program, as well as for the ongoing strategy, coordination and integration of the research effort at Amgen sites in Thousand Oaks, CA; San Francisco, CA; Seattle, WA; Burnaby, BC; and Cambridge, MA. Before joining Amgen, Dr. Begley amassed over 20 years of clinical experience in medical oncology and hematology. His research focused on translational clinical trials and regulation of hematopoietic cells. His early studies first described human G-CSF, ad in later clinical studies, he first demonstrated that G-CSF “mobilized” blood stem cells hastened hematopoietic recovery, compared with bone marrow transplantation. This discovery has revolutionized the approach to hematopoietic cell transplantation. He is Board Certified in Australia as a Medical Oncologist and Hematologist (FRACP), and Laboratory Hematologist (FRCPA, Australia; FRCPath, United Kingdom) and has a PhD in cellular and molecular biology. He has published over 200 papers that have been cited over 12,000 times. He has received numerous honors and awards, including being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, and to the prestigious Association of American Physicians in 2008.

Henry R. Bourne

Henry R. Bourne, MD received his MD from Johns Hopkins University in 1965, where he was trained in internal medicine and spent two “yellow beret” years in research at the National Institutes of Health. After a fellowship in the School of Medicine of the University of California, San Francisco (UCSF), Dr. Bourne joined the faculty in 1971 and has remained at UCSF ever since. Dr. Bourne analyzed mutations affecting synthesis and action of cyclic AMP in cultured cells. From 1977 – 2000, his research focus turned toward mutations in genes encoding trimeric G-proteins and G-protein coupled receptors. In 2000, he switched to neutrophil polarity and chemotaxis. At UCSF, Dr. Bourne served as Chair of the Department of Pharmacology (1984 – 1993). His research accomplishments were recognized by selection as UCSF’s Faculty Research Lecturer in 1991 and election to the National Academy of Sciences and American Academy of Arts and Sciences. After retiring from active research in 2008, Bourne authored a memoir, Ambition and Delight (2009) and a history of scientific discovery, Paths to Innovation (U California Press, 2012), as well as essays in Science and eLife on problems faced by the US biomedical research enterprise.

Paul Braunschweiger

Paul Braunschweiger earned his PhD at the University of Buffalo. After spending time at Allegheny General Hospital in Pittsburgh PA and at AMC Cancer Center in Denver, Colorado, he came to the University of Miami in 1990, and in 1994 was promoted to Professor in the Department of Radiation Oncology, at the Sylvester Cancer Center in the Miller Medical School. Dr. Braunschweiger conducted NIH funded basic research in the sensitivity of tumor cells to ionizing radiation and has authored numerous peer reviewed papers on experimental cancer therapeutics and cellular radiation sensitivity. In 1997, Dr. Braunschweiger was appointed Chair of the University of Miami Institutional Animal Care and Use Committee and Director of the Office of the IACUC. He held this University-wide committee chairmanship position for nearly 13 years. In 2000, Dr. Braunschweiger founded the Collaborative Institutional Training Initiative (CITI) Program. CITI, administered at the University of Miami, now provides a multi-language, customizable web based instructional program (http://www.citiprogram.org) in Human Subjects Protection and the Responsible Conduct of Research to over 2000 organizations around the world. More than 3 million people have completed a CITI Program course since September, 2000. Currently more than 70,000 courses per month are served to the global research community. In 2006 Dr. Braunschweiger launched the CITI RCR Working Group and in May 2007, Dr. Braunschweiger and Dr. Mike Fallon, at the Atlanta VA, completed an adaptation of the VA’s basic animal welfare training program (researchtraining.org) to the CITI presentation paradigm to create the CITI Lab Animal Welfare Program. Dr. Braunschweiger was named the CEO of the CITI Program at the University of Miami in 2011. Dr. Braunschweiger teaches research ethics to graduate students and fellows at the University of Miami. He has served as a study section reviewer for the NIH and has received funding from the Department of the Navy, the Department of Energy and the ORI for ethics education projects. Dr. Braunschweiger received an NIH/Fogarty Foundation grant to support the Pan American Bioethics Initiative (PABI) and to facilitate the development of research ethics education programs in Latin America and the Caribbean.

J. G. (Jerry) Collins

J.G. (Jerry) Collins, PhD is Professor Emeritus of and Senior Research Scientist in Anesthesiology at the Yale University School of Medicine. Jerry holds a BS in Biology and PhD in Pharmacology from the University of Pittsburgh and was awarded an honorary MS from Yale. In addition to an active research and teaching career, Jerry dedicated a significant portion of his professional time to educating the public about the process of science and the role that animal models play in that endeavor. In 1998 he was appointed Chair of the Yale University Institutional Animal Use and Care Committee (IACUC), an appointment that focused his educational efforts on IACUC functions and processes; Jerry stepped down from the chairmanship in 2008. Since 1998 Jerry has served frequently as a member of the faculty for PRIMR and SCAW IACUC educational meetings. He was invited to join the faculty of IACUC 101 in 2001 and continues to serve as a member of the IACUC 101 core faculty. Jerry was selected as an ad hoc site- visitor for The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) in 2003, was elected to the AAALAC Council on Accreditation in 2007, and served on Council until accepting a position as a consultant, on a part-time basis (IPA-MP), with the NIH Office of Laboratory Animal Welfare (OLAW), Division of Policy and Education. Jerry worked as a consultant to OLAW from 2009 until 2013 where his charge was to assist in the development of educational outreach programs for IACUC committee members and staff at OLAW assured institutions. In addition to ongoing teaching and administrative responsibilities at Yale, Jerry currently serves as a senior advisor to the Yale University Vice President for Research Administration on IACUC related issues and provides private consultation to institutions interested in improving their IACUC processes.

Gaylen Edwards

Gaylen Edwards, DVM, PhD is the Georgia Athletic Associate Professor of Veterinary Medicine and Head of the Department of Physiology and Pharmacology at the University of Georgia. He received his BS from Idaho State University, his MS from the University of Idaho, and both his DVM and PhD from Washington State University. He served as a postdoctoral fellow at the Cardiovascular Center at the University of Iowa, and has spent the majority of his academic career at the University of Georgia. He has also served as the Chair of the Neuroscience Division of the Biomedical Health Sciences Institute at the University of Georgia
and as a council member for AAALAC International.

Jeffrey Everitt

Jeffrey Everitt received his DVM from Cornell University in 1977 and then served as a resident and lecturer in comparative pathology at the University of Pennsylvania before completing a postdoctoral research appointment at the University of Illinois. Dr. Everitt served for 17 years on the senior scientific staff of the CIIT Centers for Health Research in Research Triangle Park, NC where he attained Senior Scientist status. He currently serves as site lead in the global Department of Laboratory Animal Sciences at GlaxoSmithKline. Dr. Everitt is a Diplomate of the American College of Veterinary Pathologists and the American College of Laboratory Animal Medicine, and is a Fellow in the International Academy of Toxicologic Pathologists. He holds adjunct faculty appointments in the Department of Pathology and Laboratory Medicine at the UNC School of Medicine in Chapel Hill, NC and in the North Carolina State University College of Veterinary Medicine in Raleigh, NC. Dr. Everitt served on the Council of ILAR from 2004-2010 and has held multiple leadership roles in professional organizations in pathology, toxicology and laboratory animal science. His research interests include toxicologic and comparative pathology as well as the use of animal models in biomedical research.

Michael FW Festing

Michael FW Festing obtained a BSc and MSc in agriculture and a DSc from London University, UK and has a PhD in quantitative genetics from Iowa State University, USA. He is a Chartered Statistician (CState.) and is the author of over 200 scientific papers on laboratory animal genetics, experimental design and related topics. Before retiring in 2004 he worked in the Medical Research Council Laboratory Animals Centre, then the MRC Toxicology Unit, Leicester University. He continues to be a frequent lecturer on experimental design and statistics for scientists seeking a project licence for work on animals under UK legislation and is a joint author of The Design of Animal Experiments (Festing MFW, Overend P, Gaines Das R, Cortina Borja M and Berdoy M, 2002), Laboratory Animals Ltd., London). He has received a number of animal welfare-associated awards including the GV-SOLAS 1st. prize (1990/1991) for a paper entitled “The scope for improving the design of laboratory animal experiments”, the 1st. Charles River award (1995) for “A lifetime dedication to laboratory animal science and welfare”, The 3rd. (1996) SmithKline Beecham laboratory animal welfare prize for “outstanding contribution to the welfare of laboratory animals”, the “Recognition Award” from Johns
Hopkins University Center for Alternatives to Animal Testing, the Doerenkamp-Zbinden Foundation medal of honor for animal welfare, and Honorary membership in the American College of Laboratory Animal Medicine (ACLAM). 

Gilly Griffin

Gilly Griffin, PhD is the Director of Standards at the Canadian Council on Animal Care, where she has worked for the past 19 years. She trained as a physiologist in the UK and has a background in both biomedical and agricultural research, the common link being the study of insulin and related hormones. Dr. Griffin has also spent many years working to further the concept of the Three Rs: as a research scientist; as managing editor of ATLA, the peer-review journal published by the UK-based Fund for the Replacement of Animals in Medical Experiments; and as Executive Director of the Canadian Centre for Alternatives to Animals in Research. She now heads the Standards sector of the CCAC, where she continues to develop guidelines, champion the principles of the Three Rs, and foster national and international collaborations to improve the ethical use of animals in science.

Coenraad F. M. Hendriksen

Coenraad F. M. Hendriksen studied veterinary medicine at the Faculty of Veterinary Medicine, Utrecht University, the Netherlands. He obtained his PhD in 1989 on a thesis entitled “Alternatives to Animal Testing in Diphtheria and Tetanus Research”. That same year, he became the animal welfare officer at the National Institute for Public Health and the Environment (RIVM) in the Netherlands and coordinator of RIVM’s institutional centre on alternatives (CAD). Following that position, he worked on test model development with a particular interest in the development and validation of replacement, reduction and refinement alternatives to laboratory animal use. Currently, he is animal welfare officer a the Institute for Translational Vaccinology (Intravacc) and programme-leader for Intravacc projects on alternatives to animal testing. Since 2000, Hendriksen holds a chair on Alternatives to Animal Use at the Faculty of Veterinary Medicine, Utrecht University. He is a member of several national and international committees, including the Central Committee on Animal Experimentation (chairman) in the Netherlands, the Mirror Group of the European Partnership on Alternative Approaches to Animal Testing (EPAA) of the European Commission and EPAA’s Vaccine Project Committee. Hendriksen served as a member of the ILAR Council from 2002 – 2008 and was chair of the committee for the 2008 ILAR Workshop on Animal Research in a Global Environment: Meeting the Challenges. He has been recognised for his research by receiving the Russell & Burch award, the Doerenkamp-Zbinden award, the Felix Wanklel Tierschutz award, and the ZonMw Prize.

John P. A. Ioannidis

John P. A. Ioannidis holds the C.F. Rehnborg Chair in Disease Prevention at Stanford University; is Professor of Medicine, Professor of Health Research and Policy, and Director of the Stanford Prevention Research Center at Stanford University School of Medicine; Professor of Statistics (by courtesy) at Stanford University School of Humanities and Sciences; Director of the Meta-Research Innovation Center at Stanford; member of the Stanford Cancer Institute and of the Stanford Cardiovascular Institute, affiliate in the Stanford Center on Longevity, and affiliated faculty of the Woods Institute for the Environment. Dr. Ioannidis grew up in Athens, Greece. He was Valedictorian of his class (1984) at Athens College and won a number of early awards, including the National Award of the Greek Mathematical Society in 1984. He graduated in the top rank of his medical school class from the University of Athens in 1990 and received a doctorate in biopathology from the same institution. He trained at Harvard and Tufts, specializing in internal medicine and infectious diseases, then held positions at NIH, Johns Hopkins and Tufts. From 1999 until 2010 he chaired the Department of Hygiene and Epidemiology at the University of Ioannina Medical School in Greece as a tenured professor since 2003. He has been adjunct faculty for the Tufts University School of Medicine since 1996, with the rank of professor since 2002 and led (2008-2010) the Genetics/Genomics component of the Tufts Clinical and Translational Science Institute (CTSI) and the Center for Genetic Epidemiology and Modeling (CGEM) at Tufts. He has also been adjunct professor of epidemiology at the Harvard School of Public Health and visiting professor of epidemiology and biostatistics at Imperial College London. He is a member of the executive board of the Human Genome Epidemiology Network and senior advisor on knowledge integration at the National Cancer Institute and has served as President of the Society for Research Synthesis Methodology, as a member of the editorial boards of 30 leading international journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, Journal of the National Cancer Institute, Science Translational Medicine, Clinical Chemistry, Molecular and Cellular Proteomics, AIDS, International Journal of Epidemiology, Journal of Clinical Epidemiology, Clinical Trials, Cancer Treatment Reviews, and PLoS ONE, among others) and as Editor-in-Chief of the European Journal of Clinical Investigation since 2010. He has given more than 300 invited and honorary lectures, has received several awards (including the European Award for Excellence in Clinical Science for 2007), has been inducted in the Association of American Physicians in 2009 and in the European Academy of Cancer Sciences in 2010 and was elected Honorary Member of the Foundation for Research and Technology-Hellas (FORTH) in 2014. The PLoS Medicine paper on “Why most Published Research Findings are False,” has been the most-accessed article in the history of Public Library of Science (exceeding 1 million hits). The Atlantic selected Ioannidis as the Brave Thinker scientist for 2010 claiming that he “may be one of the most influential scientists alive.” He considers himself privileged to have learnt and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and to be constantly reminded that he knows next to nothing.

Jonathan Kimmelman

Jonathan Kimmelman, PhD is Associate Professor at McGill University in Biomedical Ethics Unit / Social Studies of Medicine, with a cross appointment in Experimental Medicine. His research centers on ethical, policy, and scientific dimensions of drug and diagnostics development, and is leading a project examining the relationship between preclinical research practices and concordance with clinical outcomes. In addition to his book, Gene Transfer and the Ethics of First-in-Human Experiments (Cambridge Press, 2010), major publications have appeared in Science, PLoS Medicine, BMJ, and Hastings Center Report. Dr. Kimmelman received the Maud Menten New Investigator Prize (2006), a CIHR New Investigator Award (2008), and a Bessel-Humboldt Award (2014). He has served on various advisory bodies within the National Heart Lung and Blood Institute, the Institute of Medicine, and the Canadian Institutes for Health Research. He currently chairs the ethics committee of the International Society of Stem Cell Research.

Stephen R. Latham

Stephen R. Latham, JD, PhD is Director of the Interdisciplinary Center for Bioethics at Yale University. A graduate of Harvard College, Harvard Law School, and University of California – Berkeley’s doctoral program in Jurisprudence, Dr. Latham is a former healthcare business and regulatory attorney, and served as Director of Ethics Standards at the AMA before entering academia full time. Dr. Latham has been a graduate fellow of Harvard’s Safra Center on Ethics; a Research Fellow of the University of Edinburgh’s Institute for Advanced Studies in the Humanities; and a vice-chair of the ABA Health Law Section’s Interest Group on Medical Research, Biotechnology and Clinical Ethics. He has served on Connecticut public health committees on stem cell research, pandemic preparedness, and biobanking, and is currently a member of the Medical REview Board of the state’s Department of Children and Families. At Yale, he chairs the Human Subjects Committee and serves on the Embryonic Stem Cell Research Oversight Committee and the Pediatric Ethics Committee of Yale-New Haven Children’s Hospital. He is a former board member of the American Society for Bioethics and Humanities, from which he received a Distinguished Service Award in 2010. Dr. Latham is widely published in bioethics and health law, and currently serves as contributing editor of the Hastings Center Report, and Associate Editor for the upcoming 4th Edition of the Encyclopedia of Bioethics.

Elizabeth Marincola

Elizabeth Marincola received her undergraduate degree from Stanford University in 1981 and her MBA from the Stanford Graduate School of Business in 1986. She is CEO of PLOS (the Public Library of Science), a nonprofit organization based in San Francisco which was founded to transform science communication. PLOS has been a leader in the Open Access movement, publishing more OA articles in 2013 than any other publisher. Marincola was Executive Director of the American Society for Cell Biology (ASCB) and publisher of Molecular Biology of the Cell from 1991 – 2005, served on the first National Advisory Committee to PubMed Central of the National Institutes of Health from 2000-2003, and was Director of the Joint Steering Committee for Public Policy from 1991-2005. In 2002, the ASCB named her (with the late actor and advocate Christopher Reeve) the first Citizen Member of the Society; she accepted the (U.S.) Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring in 2005. Marincola has published widely, including in The Huffington Post, Science, and The Harvard Business Review. She gave a TedMed talk in Washington, D.C., in 2013. She was President of the Society for Science & the Public and publisher of Science News from 2005-2013. Marincola served on PLOS’ Board of Directors from 2005-2011, and was Chair of the Board of eLife before joining PLOS as CEO.

Damian Pattinson

Damian Pattinson obtained his PhD in neuroscience from University College London, where he studied the development of sensory pathways in the laboratory of Prof Maria Fitzgerald. After a brief postdoc at Kings College London, Damian joined the BMJ as a Scientific Editor on Clinical Evidence. He moved over to the online clinical resource, BMJ Best Practice shortly after its conception, firstly as Commissioning Editor, and then later as Senior Editor. He joined PLOS ONE in February 2010 as Executive Editor, where he oversaw the rapid expansion of the journal, and the introduction of new metrics to enhance the visibility of published papers, and became Editorial Director in October 2012.

Jan Piotrowski

Jan Piotrowski is The Economist’s São Paulo bureau chief. Previously, he was the Online Science Editor from 2010, having joined The Economist following a three-month stint as the Richard Casement science intern in 2008. He wrote extensively on research in various areas, from evolutionary psychology to fundamental physics, as well as contemporary problems with the scientific method. He is a regular contributor to “The World In” annual compilation of forecasts, which examines the critical issues that will shape the year ahead, as well as a number of Economist blogs, including Americas View, Babbage and Game Theory. Mr. Piotrowski holds a PhD in linguistics and philosophy of language from Warsaw University, where he lectured in semantics and translation theory. Before joining The Economist, he also worked as a translator and interpreter.

Ghislaine Poirier

Dr. Ghislaine Poirier is a veterinarian with a European specialisation in Laboratory Animal Medicine (DipECLAM). She gained a PhD in immunology from University College London and has worked as a researcher for a number of years before taking up a role as laboratory animal veterinarian. She has worked at GlaxoSmithKline as a Named Veterinary Surgeon for several years prior to moving to the Office of Animal Welfare Ethics and Strategy, where she currently leads a project aimed at optimising the use of animal models in drug R&D through animal research data sharing and re-use.

Roger H. Reeves

Roger H. Reeves, PhD is a Professor in the Department of Physiology at the Johns Hopkins University School of Medicine. He recieved his BS from Bowling Green State University and his PhD from the University of Maryland, College Park. Dr. Reeves came to Hopkins as a postdoctoral fellow in 1983 and began working on gene expression in Down syndrome (DS) almost immediately. He was a co-developer with Muriel Davisson of her Ts65Dn mouse, the most widely used model for studies of DS. He is noted for his contributions to the study of gene dosage effects and for the use of animal models to understand pathogenesis of DS. He has collaborated with Joan Richtsmeier to understand effects of trisomy on development of the midface; they have been co-PIs on various grants since the mid-1990’s. Reeves’ laboratory is currently studying possible therapeutic approaches for DS features in mouse models. Recent work in human populations includes genetic studies to identify genetic modifiers that contribute to a more or less severe presentation of DS (heart, face, cognition). He is a principal investigator at the Johns Hopkins site for the current Roche Clinical Trial of RG1662, a drug that may ameliorate cognitive effects of DS.

Jeffrey Rogers

Jeffrey Rogers, PhD is an Associate Professor in the Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. Dr. Rogers’ work is focused on the use of nonhuman primates in biomedical and basic biological research, with special interest in genetics and genomics. Dr. Rogers is responsible for the design and implementation of various genomic analyses of nonhuman primates at the HGSC, including a broad survey of genetic variation in the most widely used laboratory primate (rhesus macaques) and the de novo sequencing and assembly of the genomes of additional primates (baboon, mouse lemur, pig-tailed macaque and others). Dr. Rogers’ research also includes studies using nonhuman primates as animal models for the investigation of genetic risk factors for psychiatric illnesses such as anxiety disorders and depression. He holds a B.A. in Anthropology from Northwestern University and a PhD in Anthropology from Yale University. He is a Core Scientist at the Wisconsin National Primate Research Center (Madison, WI), Chairman of the Genetics and Genomics Working Group within the NIH National Primate Research Center Consortium and serves on the Scientific Advisory Boards for the Yerkes National Primate Research Center and the Duke Lemur Center.

Victoria Stodden

Victoria Stodden is assistant professor of statistics at Columbia University. Stodden has served on the National Academies of Science committee on “Responsible Science: Ensuring the Integrity of the Research Process. She has developed software platforms (ResearchCompendia.org, RunMyCode.org, SparseLab) and written many articles and recommendations (e.g. the “Reproducible Research Standard”) and has testified before the Congressional House Science, Space and Technology Committee on Scientific Transparency and Integrity. In 2014, she published two co-edited volumes, Implementing Reproducible Research (see https://osf.io/s9tya/wiki/home/) and Big Data, Privacy, and the Public Good (see http://www.dataprivacybook.org). Stodden has a PhD in statistics from Stanford University and an MLS from Stanford Law School.

Monte Westerfield

Monte Westerfield, PhD is Professor of Biology and Member of the Institute of Neuroscience at the University of Oregon, Eugene. He established and directs the Zebrafish International Resource Center and ZFIN, the zebrafish model organism database. He studies Usher syndrome, the leading cause of combined deafness and blindness in human and has used zebrafish models to validate disease causing gene variants in human patients. Prior to joining the faculty at Oregon, Dr. Westerfield received an AB from Princeton University in Biophysics and a PhD from Duke University Medical School in Physiology and Pharmacology, and he trained as a Fulbright Scholar at the Max Planck Institute in Munich, Germany and in Neurobiology at Harvard Medical School. He has been awarded Sloan, Fogarty and Guggenheim Fellowships, the Talbot Award, the McKnight Development Award, the Medical Research Foundation Award, and the Von Humboldt Prize. Dr. Westerfield serves on the Advisory Council to NIH NIDCD.

Stuart M. Zola

Stuart M. Zola, PhD currently serves as a Professor, Psychiatry and Behavioral Sciences, at the Emory University School of Medicine; the Co-Director of the Emory Alzheimer’s Disease Research Center; and Senior Research Career Scientist at the Atlanta Veterans Affairs Medical Center. One of the nation’s leading neuroscientists, Dr. Zola has contributed valuable insights into how the brain organizes memory and how this process relates to memory problems, such as amnesia. In 2009, the American Association for the Advancement of Science named him a fellow for his “distinguished contributions in neuroscience, including the delineation of the brain’s memory system, and for communicating the importance and excitement of science to the lay public.” As the director of the Yerkes National Primate Research Center, Dr. Zola oversees essential basic science and translational research to advance scientific understanding and to improve the health and well-being of humans and animals. Dr. Zola’s own research focuses on memory formation, consolidation and retrieval. He is perhaps best known for developing an animal model of human amnesia in nonhuman primates that conclusively identified brain structures critical to memory function. Dr. Zola’s research has contributed significant insight into the memory loss in humans that characterizes progressive diseases, such as mild cognitive impairment (MCI) and Alzheimer’s disease. In one of his current research programs, he is studying patients who have MCI as a way to identify those who later may be affected by Alzheimer’s disease.